SEC Filings
Cabaletta Bio’s Rese-cel Keeps All 6 Dermatomyositis Patients Improving At One Year
Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.
Cabaletta Bio (CABA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.
Earnings
Research spending rose to $47.1 million as Cabaletta targets a myositis approval application in the first quarter of 2028.